Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The MYC transcription factor is a key regulator of cell proliferation and is frequently overexpressed in human cancers.
• MYC's oncogenic activity stems from its binding to E-box sequences, influencing over 4000 target genes.
• Targeting MYC offers a promising strategy for novel cancer therapies.

Purpose of the Study:

• To design and characterize a novel small molecule inhibitor targeting MYC's DNA-binding activity.
• To evaluate the efficacy of the pyrrole-imidazole polyamide Myc-5 in inhibiting MYC-dependent gene expression and tumor growth.

Main Methods:

• Bioinformatics analysis to identify MYC E-box consensus sequences in target gene promoters.
• Chromatin immunoprecipitation coupled with quantitative PCR (ChIP-qPCR) to assess Myc-5's inhibition of MYC binding.
• In vitro studies in Burkitt's lymphoma (P493.6) and chronic myelogenous leukemia (K562) cell lines to measure gene and protein expression changes.
• In vivo efficacy study using a MYC-dependent tumor xenograft model in mice.

Main Results:

• Myc-5 specifically recognizes the MYC E-box consensus sequence, with predicted binding sites at eIF4G1, CCND1, and CDK4 promoters.
• Myc-5 successfully inhibited MYC binding to target gene promoters, leading to downregulation of mRNA and protein levels.
• A single intravenous dose of Myc-5 demonstrated significant inhibition of tumor growth in a xenograft model without observable toxicity.

Conclusions:

• The pyrrole-imidazole polyamide Myc-5 effectively inhibits MYC-driven gene expression by blocking MYC-E-box interactions.
• Myc-5 shows therapeutic potential as a MYC-targeted agent, demonstrating significant anti-tumor activity in preclinical models.
• This study validates a novel approach for developing MYC-targeted cancer therapies.